API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/latest-biotech-biotech-merger-sees-aimless-adamis-snapped-dmk
https://www.fiercebiotech.com/biotech/adamis-shares-nosedise-sole-unapproved-asset-flunks-covid-trial
https://www.globenewswire.com/news-release/2022/09/21/2520081/32832/en/Adamis-Provides-Update-on-the-Phase-2-3-Trial-of-Tempol-in-COVID-19-Positive-High-Risk-Subjects.html
https://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-provides-enrollment-update-phase-23-study-tempol-covid-19
https://www.clinicaltrialsarena.com/news/adamis-trial-tempol-covid/
https://www.globenewswire.com/news-release/2021/09/02/2290774/32832/en/Adamis-Pharmaceuticals-Doses-First-Patients-in-Phase-2-3-Clinical-Trial-for-Tempol-in-the-Treatment-of-COVID-19.html
http://ir.adamispharmaceuticals.com/news-releases/news-release-details/adamis-pharmaceuticals-cleared-proceed-human-studies-tempol